About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.
MetaSystems DM2019 Largest in History
XL t(4;14) FGFR3/IGH DF
Translocation/Dual Fusion Probe
- Order Number
- D-5108-100-OG
- Package Size
- 100 µl (10 Tests)
- Regulatory Status
- IVDD
IVDR Certification
This probe is IVDR-certified in compliance with the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR).
MetaSystems Probes has already certified a large part of its portfolio, according to IVDR. For organizational reasons, we currently provide only the IVDD product.
XL t(4;14) FGFR3/IGH DF consists of an orange-labeled probe hybridizing to the FGFR3 gene region at 4p16.3 and a green-labeled probe hybridizing to the IGH gene region at 14q32.3.
Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.
The most frequent primary abnormalities in multiple myeloma (MM) are trisomies of odd-numbered chromosomes or translocations involving the immunglobulin heavy chain (IGH) gene locus. The most common MM-associated IGH translocations are t(11;14), t(4;14), t(6;14), t(14;16) and t(14;20) in the order of their occurrence. The consequence of these rearrangements is the dysregulation of genes juxtaposed to transcriptional enhancers in the IGH locus. Prognosis and risk stratification strongly depend on the detection and interpretation of cytogenetic primary abnormalities. t(14;16) and t(14;20) are considered as high risk, t(4;14) as intermediate risk and t(6;14) and t(11;14) as standard risk cytogenetic aberrations in patients with MM based on FISH testing. Secondary aberrations are also influencing the outcome.
The recurrent translocation t(4;14)(p16;q32) is juxtaposing FGFR3 with the 3′ alpha IgH enhancer on der(14), whereas expression of NSD2 is controlled by the Eμ enhancer on der(4). FGFR3 overexpression is detectable in about 70% of t(4;14) positive MM patients, suggesting that FGFR3 dysregulation is not the crucial oncogenic event. The poor outcome of patients lacking FGFR3 expression due to the loss of der(14) is supporting this conclusion. Transcripts from the NSD2 locus on the other hand are found to be overexpressed in all t(4;14) positive MM cases, suggesting that this gene region plays a major role in the manifestation of MM.
Clinical Applications
- Multiple Myeloma and Plasma Cell Neoplasms (MM)
XL t(4;14) IGH/FGFR3 DF hybridized to lymphocytes. Two normal interphases are shown.
Normal Cell:
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two greenorange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the respective loci.
- Chesi et al (1998) Blood 92:3025-3034
- Keats et al (2003) Blood 15:4060-4069
- Rajan and Rajkumar (2015) Blood Cancer J 5:e365
Second MetaSystems User Day in Altlussheim, Germany
Neon, the outstanding MetaSystems case and image management system, offers many tools and helpful gadgets to streamline routine workflows, for example in cytogenetics labs. The second MetaSystems User Day, addressed to MetaSystems clients from Germany, Austria, and Switzerland, provided in different workshops knowledge helping to unleash the full power of the system.
OOO MetaSystems Russia on the International Scientific Congress 'Genetics of XXI Century'
The Congress 'Genetics of XXI Century' in Moscow, Russia (May 2019) has been one of the most important events for the professional international community of geneticists. Our partner company in Russia OOO MetaSystems considered it a good occasion to present the new camera CoolCube 4 connected to a state-of-the-art Neon system to the public.
